(Q44272543)

English

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

phase III clinical trial

0 references

phase II clinical trial

0 references

0 references

1 reference

ChEBI release 2020-05-28

12

object named as

John V Heymach

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

9

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Hai T Tran

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Yuan Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Amado J Zurita

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ying Lin

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Katherine L Baker-Neblett

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Anne-Marie Martin

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Robert A Figlin

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Thomas E Hutson

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Rafael G Amado

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Lini N Pandite

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

2 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

827-837

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of brain metastases in renal cell carcinoma treated with sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

More powerful procedures for multiple significance testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 evaluation and its impact on breast cancer treatment decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970241-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70241-3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44272543&oldid=2186353194"